Hexyon market report sees growth from pediatric immunization demand

The Business Research Company says the Hexyon vaccine market is set for growth through 2035, driven by broader childhood immunization, emerging-market vaccination programs and colder-chain improvements. Europe led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Hexyon is a six-in-one pediatric vaccine, so demand tracks broader efforts to simplify childhood immunization and reduce the number of injections infants receive. - The market is tied to public-health spending, pediatric coverage expansion and vaccine delivery infrastructure, making it a bellwether for immunization access.

What happened: - The Business Research Company published its Hexyon Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report says the Hexyon market is gaining attention as global efforts to improve pediatric healthcare and immunization coverage intensify. - The company released a free sample of the report and a full report for download through its website.

The details: - Hexyon protects infants and young children against diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b, or Hib. - Hexyon is typically given on a routine immunization schedule and combines multiple protections into one injection. - The report says historical growth was supported by efforts to reduce injection burdens for infants, government immunization campaigns, the safety profile of combination vaccines and a focus on preventing pediatric diseases. - The report expects growth to come from broader immunization coverage among birth cohorts, more vaccination programs in emerging markets, higher funding for pediatric healthcare, demand for cost-effective combination vaccines and better cold-chain infrastructure. - The report highlights rising adoption of combination pediatric vaccines, simplified childhood immunization schedules, greater demand for hexavalent vaccines like Hexyon, expansion of routine infant immunization programs and wider use in national health policies. - The report says Europe held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The new 2026 report format adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key-technology analysis, future-trend analysis, and updated graphics and tables. - The report links market growth to the rising pediatric population, defined in the release as people from birth to age 18. - The UK Office for National Statistics reported in August 2025 that the UK total fertility rate slipped from 1.42 to 1.41 children per woman between 2023 and 2024, even as births rose in 2024. - The release says this demographic pattern supports continued demand for pediatric vaccines like Hexyon. - The UK government’s net R&D expenditure rose 8.2% year over year in April 2025, from $20.0 billion (£16.1 billion) in 2022 to about $21.6 billion (£17.4 billion) in 2023, according to the ONS. - The release says higher R&D spending supports vaccine improvements and market growth. - The report’s sample link is available here: Download a free sample of the report. - The full report is available here: View the full market report.

Between the lines: - The release frames Hexyon as part of a broader shift toward combination vaccines that can improve adherence by making pediatric schedules simpler. - The report’s regional split suggests mature markets still matter, but the fastest growth is coming from places where vaccination coverage is still expanding. - The emphasis on cold-chain infrastructure and national policy adoption points to execution, not just demand, as a key constraint on market growth.

What's next: - The report forecasts continued market expansion through 2035. - It expects vaccination programs in emerging markets, pediatric healthcare investment and broader policy adoption to shape the next phase of growth. - The company is marketing its updated report suite with new analytics tools for buyers tracking the market.

The bottom line: - Hexyon’s market outlook is being driven less by a single product trend and more by the global push to make childhood immunization easier, broader and more cost-effective.